MedDataX Logo

Diagnosic and Pronostic Values of Kappa and Lambda Free Light Chains in Central Nervous System Inflammatory Diseases

NCT ID: NCT05088473

Last Updated: 2021-11-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-10-15

Study Completion Date

2021-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Numerous studies have shown the diagnostic interest of cerebrospinal fluid kappa free light chains and kappa index in multiple sclerosis. However, large cohort studies are lacking and little is known about the correlation between kappa and lambda indexes and multiple sclerosis evidence disease activity. Therefore, this study plan to validate the kappa and lambda free light chains and indexes as diagnostic biomarker in multiple sclerosis and to correlate the concentration of kappa and lambda free light chains with clinical and radiological activity in a large cohort of patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Central Nervous System Diseases Multiple Sclerosis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

multiple sclerosis kappa free light chains lambda free light chains

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mutliple sclerosis

Biological collection

Intervention Type OTHER

Collection of cerebrospinal fluid kappa and lambda free light chains and indexes

CIS/RIS

Biological collection

Intervention Type OTHER

Collection of cerebrospinal fluid kappa and lambda free light chains and indexes

Other CNS inflammatory diseases

Biological collection

Intervention Type OTHER

Collection of cerebrospinal fluid kappa and lambda free light chains and indexes

Non inflammatory CNS diseases

Biological collection

Intervention Type OTHER

Collection of cerebrospinal fluid kappa and lambda free light chains and indexes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biological collection

Collection of cerebrospinal fluid kappa and lambda free light chains and indexes

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients presenting with symptoms evocative of CNS involvement for who serum and cerebrospinal fluid kappa free light chains and kappa index are available

Exclusion Criteria

* Infectious CNS disease
* Tumor CNS disease
* Active CNS bleeding
* Monoclonal gammapathy
* Severe chronic renal failure (glomerular filtration rate \<30 ml/mn)
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire de Nice

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier Universitaire de Clermont-Ferrand

Clermont-Ferrand, , France

Site Status

Centre Hospitalier Universitaire de Dijon

Dijon, , France

Site Status

Centre Hospitalier Universitaire de Grenoble

Grenoble, , France

Site Status

Centre Hospitalier Universitaire de Lille

Lille, , France

Site Status

Assistance Publique des Hôpitaux de Marseille

Marseille, , France

Site Status

Centre Hospitalier Universitaire de Montpellier

Montpellier, , France

Site Status

Centre Hospitalier Universitaire de Nantes

Nantes, , France

Site Status

Centre Hospitalier Universitaire de Nice

Nice, , France

Site Status

Centre Hospitalier Universitaire de Nîmes

Nîmes, , France

Site Status

Assistance Publique des Hôpitaux de Paris

Paris, , France

Site Status

Centre Hospitalier Universitaire de Saint-Etienne

Saint-Etienne, , France

Site Status

Centre Hospitalier Universitaire de Strasbourg

Strasbourg, , France

Site Status

Centre Hospitalier Universitaire de Toulouse

Toulouse, , France

Site Status

Centre Hospitalier Régional et Universaitaire de Tours

Tours, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

21Neuro01

Identifier Type: -

Identifier Source: org_study_id